The radiation oncology perspective

Seminars in Breast Disease

Volumn 4, Issue 4, 2001, Pages 191-197

  Jacobs, M C E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE;

EID: 0035668593     PISSN: 10924450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Management of locally recurrent breast cancer
2. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy
3. Preoperative evaluation of abnormal mammographic findings to avoid unnecessary breast biopsies
4. Incidence of and treatment for ductal carcinoma in situ of the breast
5. Frequency, sites of relapse, and outcome of regional nude failures following conservative surgery and radiation for early breast cancer
6. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma
7. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data
8. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute trials
9. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
10. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer
11. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial
12. The surgical perspective
13. Imaging the local extent of disease
14. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4)
15. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy
16. Impact of extensive intraductal component on recurrence and survival in patients with stage I or II breast cancer treated with breast conservation therapy
17. Extent of margin positivity as a predictor for local recurrence after breast: Conserving irradiation
18. Outcome 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence
19. Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: Experience of the Institut Gustave-Roussy
20. The "boost" in the treatment of early-stage breast cancer: Electrons versus interstitial implants
21. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer
22. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation
23. The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial
24. Postmastectomy radiotherapy: Randomized trials
25. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials
26. The link between local recurrence and distant metastases in human breast cancer
27. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination
28. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial
29. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
30. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastecromy irradiation
31. Consensus Statement on postmastecromy radiation therapy
32. Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. The experience of the Institut Gustave-Roussy
33. The relationship between lymphatic vessel invasion, tumor size, and pathologic nodal status: Can we predict who, can avoid a third field in the absence of axillary dissection?
34. The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer
35. Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy
36. Should internal mammary, lymph nodes in breast cancer be a target for the radiation oncologist?
37. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer
38. Eight-year results of a randomized clinical trial comparing total mastectomy and mpectomy with or without irradiation in the treatment of breast cancer
39. Definitive irradiation for intraductal carcinoma of the breast
40. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
41. Fifteen-year results of breast- conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast
42. Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast
43. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
44. The influence of margin with on local control of ductal carcinoma in situ of the breast
45. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience